Clinica Chimica Acta:利用ADVIA Centaur XPT平台对hs-cTnI方法第99百分位数和参考值进行评价

2019-09-21 gladiator MedSci原创

根据国际准则质量规范的要求,第99个URL值的评估是一项非常困难的任务,通常超出单个实验室的能力。本文的目的是报告和讨论一项多中心研究的结果,该研究评估了最近意大利临床实验室的ADVIA Centaur高灵敏度肌钙蛋白I (TNIH)的第99百分位URL和参考值变化(RCV)。

根据国际准则质量规范的要求,第99URL值的评估是一项非常困难的任务,通常超出单个实验室的能力。本文的目的是报告和讨论一项多中心研究的结果,该研究评估了最近意大利临床实验室的ADVIA Centaur高灵敏度肌钙蛋白I (TNIH)的第99百分位URL和参考值变化(RCV)

参考人口评估ADVIA XPT材料cTnI参考分布参数的计算方法是基于1325名健康成年人的对象(年龄从18-86),包括653名妇女(平均年龄50.7SD14.5)672名男性(平均年龄50.9SD13.8),以及匹配两个年龄(P=.8112)和性(F / M=0.97)的。

研究显示,参考群体的cTnI分布呈高度偏态,而对数变换后的cTnI值近似于对数正态分布。在整个成年期,男性的cTnI值都高于女性。此外,受试者年龄 ≤55  岁cTnI值明显低于那些 >55 年(p< 。)。值得注意的是,62%的女性和77%的男性的cTnI值等于或高于该方法的LoD(即 2.2 ng / L)

本研究的结果表明,使用XPT自动化平台的ADVIA Centaur高灵敏度肌钙蛋白I符合最新的国际cTnI高灵敏度方法指南所要求的标准和质量规范。

原始出处:

Aldo ClericoSilvia MasottiEvaluation of 99th percentile and reference change values of the hs-cTnI method using ADVIA Centaur XPT platform: A multicenter study

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2028071, encodeId=60b620280e158, content=<a href='/topic/show?id=7935541934' target=_blank style='color:#2F92EE;'>#cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5419, encryptionId=7935541934, topicName=cTnI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon May 25 13:11:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947811, encodeId=4b1f194e8114a, content=<a href='/topic/show?id=c67f913106' target=_blank style='color:#2F92EE;'>#Hs-cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9131, encryptionId=c67f913106, topicName=Hs-cTnI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 15 06:11:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849724, encodeId=cea71849e2444, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 23 14:11:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444574, encodeId=927114445e40b, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509280, encodeId=76a91509280b6, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
    2020-05-25 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=2028071, encodeId=60b620280e158, content=<a href='/topic/show?id=7935541934' target=_blank style='color:#2F92EE;'>#cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5419, encryptionId=7935541934, topicName=cTnI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon May 25 13:11:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947811, encodeId=4b1f194e8114a, content=<a href='/topic/show?id=c67f913106' target=_blank style='color:#2F92EE;'>#Hs-cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9131, encryptionId=c67f913106, topicName=Hs-cTnI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 15 06:11:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849724, encodeId=cea71849e2444, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 23 14:11:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444574, encodeId=927114445e40b, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509280, encodeId=76a91509280b6, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2028071, encodeId=60b620280e158, content=<a href='/topic/show?id=7935541934' target=_blank style='color:#2F92EE;'>#cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5419, encryptionId=7935541934, topicName=cTnI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon May 25 13:11:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947811, encodeId=4b1f194e8114a, content=<a href='/topic/show?id=c67f913106' target=_blank style='color:#2F92EE;'>#Hs-cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9131, encryptionId=c67f913106, topicName=Hs-cTnI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 15 06:11:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849724, encodeId=cea71849e2444, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 23 14:11:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444574, encodeId=927114445e40b, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509280, encodeId=76a91509280b6, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
    2020-01-23 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=2028071, encodeId=60b620280e158, content=<a href='/topic/show?id=7935541934' target=_blank style='color:#2F92EE;'>#cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5419, encryptionId=7935541934, topicName=cTnI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon May 25 13:11:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947811, encodeId=4b1f194e8114a, content=<a href='/topic/show?id=c67f913106' target=_blank style='color:#2F92EE;'>#Hs-cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9131, encryptionId=c67f913106, topicName=Hs-cTnI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 15 06:11:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849724, encodeId=cea71849e2444, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 23 14:11:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444574, encodeId=927114445e40b, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509280, encodeId=76a91509280b6, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
    2019-09-23 huagfeg
  5. [GetPortalCommentsPageByObjectIdResponse(id=2028071, encodeId=60b620280e158, content=<a href='/topic/show?id=7935541934' target=_blank style='color:#2F92EE;'>#cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5419, encryptionId=7935541934, topicName=cTnI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon May 25 13:11:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947811, encodeId=4b1f194e8114a, content=<a href='/topic/show?id=c67f913106' target=_blank style='color:#2F92EE;'>#Hs-cTnI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9131, encryptionId=c67f913106, topicName=Hs-cTnI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 15 06:11:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849724, encodeId=cea71849e2444, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 23 14:11:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444574, encodeId=927114445e40b, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509280, encodeId=76a91509280b6, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Mon Sep 23 14:11:00 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
    2019-09-23 szhvet

相关资讯

CHEST:种族不同也可以影响呼出气一氧化氮!

呼出一氧化氮(FeNO)在临床上被用作嗜酸性气道炎症的生物标志物。了解影响FeNO值的因素对于临床解释是十分重要的。近期,一项发表在杂志CHEST上的文章对PubMed,Cochrane图书馆,Scopus和Web of Science数据库进行了系统评价,以评估种族是否影响FeNO值,并根据当前指南确定这种影响是否影响临床解释。研究者们最终筛选了至少包含25名健康非白种人的在线FeNO测量的研究

Hepatology:儿童ALT、AST、GGT新参考值:年龄、性别、BMI和青春发育期的影响

结论:采用现代分析方法和统计方法,计算11个月到16.0岁儿童ALT、AST和GGT血清水平的当前参考值。该项研究揭示出年龄、性别、身体质量指数和青春期对三个参数的血清浓度的影响,并且这些参数由迄今为止最大的样本量计算得出。

肿瘤标志物HE4中国人群参考值研究结果发布

人附睾蛋白4(human epididymis protein 4,HE4)作为一种新的肿瘤标志物,在良性疾病患者和正常人血清中含量极低,而在卵巢癌组织和患者血清中均高度表达。在日前上海举行的“血清肿瘤标志物在卵巢癌诊疗中的临床应用”研讨会上,解放军总医院田亚平教授首次公布了HE4中国人群参考值大型临床研究的结果。这一历时两年的多中心、大样本的临床研究,由解放军总医院、天津市肿瘤医院等9家医院联合

CHEST:健康人运动时的心输出量参考值与计算方程式

心输出量(Q)是评估心脏功能的关键参数,其测量对于所有心脏病的诊断、治疗和预后评估至关重要。直到最近,在峰值运动的Q测定已经可能通过侵入性方法实现,使得可以在基于小群体的研究中获得正常值。如今,峰Q可以通过惰性气体再呼吸技术(IGR)无创测量。进行研究以提供正常群体中峰Q的参考值,并获得能够从测量的峰值氧摄取(VO2)估计峰值运动Q的公式。研究者研究了500名正常受试者(年龄44.9±1.5岁,范

Clinica Chimica Acta:瘦素/脂联素比值在健康儿童和青少年中的参考值

众所周知,瘦素和脂联素是脂肪细胞分泌的两种重要激素,它们参与多种重要的生理机制。由于瘦素 · 2019-08-08

-->